Market closedNon-fractional

Vor Biopharma/VOR

13:30

15:10

16:45

18:25

20:00

1D1W1MYTD1YMAX

About Vor Biopharma

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Ticker

VOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

168

Website

www.vorbio.com

Vor Biopharma Metrics

BasicAdvanced

$65M

Market cap

-

P/E ratio

-$1.78

EPS

-0.24

Beta

-

Dividend rate

Price and volume

Market cap

$65M

Beta

-0.24

Financial strength

Current ratio

8.463

Quick ratio

8.134

Long term debt to equity

25.019

Total debt to equity

28.235

Management effectiveness

Return on assets (TTM)

-35.97%

Return on equity (TTM)

-68.07%

Valuation

Price to book

0.53

Price to tangible book (TTM)

0.53

Price to free cash flow (TTM)

-0.598

Growth

Earnings per share change (TTM)

-14.93%

3-year earnings per share growth (CAGR)

-43.18%

What the Analysts think about Vor Biopharma

Analyst Ratings

Majority rating from 9 analysts.

Buy

Vor Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses

0.00% profit margin

QuarterlyAnnual

Q1 24

QoQ growth

Revenue

$0

NaN%

Net income

-$31M

17.56%

Profit margin

0.00%

NaN%

Vor Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability

Missed by 18.87%

QuarterlyAnnual

Q2 23

Q3 23

Q4 23

Q1 24

Q2 24

Actual

-$0.45

-$0.49

-$0.39

-$0.45

-

Expected

-$0.43

-$0.47

-$0.50

-$0.38

-$0.42

Surprise

4.09%

4.58%

-22.52%

18.87%

-

Vor Biopharma News

AllArticlesVideos

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·2 weeks ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·2 months ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewsWire·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon

Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Vor Biopharma stock?

Vor Biopharma (VOR) has a market cap of $65M as of July 27, 2024.

What is the P/E ratio for Vor Biopharma stock?

The price to earnings (P/E) ratio for Vor Biopharma (VOR) stock is 0 as of July 27, 2024.

Does Vor Biopharma stock pay dividends?

No, Vor Biopharma (VOR) stock does not pay dividends to its shareholders as of July 27, 2024.

When is the next Vor Biopharma dividend payment date?

Vor Biopharma (VOR) stock does not pay dividends to its shareholders.

What is the beta indicator for Vor Biopharma?

Vor Biopharma (VOR) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.

Buy or sell Vor Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.

Start investing